middle.news
How Amplia’s Narmafotinib is Redefining Pancreatic Cancer Treatment
9:14am on Thursday 31st of July, 2025 AEST
•
Healthcare
Read Story
How Amplia’s Narmafotinib is Redefining Pancreatic Cancer Treatment
9:14am on Thursday 31st of July, 2025 AEST
Key Points
ACCENT trial shows 31% response rate with 17 partial responses
Two patients achieved rare complete responses, including metastatic pancreatic cancer
Ethics approvals secured for second narmafotinib trial with FOLFIRINOX chemotherapy
Appointment of Dr Jason Lickliter as Chief Medical Officer
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE